BioSpace: Biotech, Pharmaceutical and Clinical Research News
网页2024 Q2 Job Market Report: More People Competing for Fewer Job Openings. For the second quarter of 2024, there were 25% fewer jobs posted live on BioSpace compared to the same quarter of 2023. The year-over-year job response rate rose from 14.6% to 15.3%. July 11, 2024. ·.
News - BioSpace
网页September 12, 2024. ·. 4 min read. ·. Angela Gabriel. Load More. BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The latest biotech and pharmaceutical news ...
China - BioSpace
网页Well-financed startup Tome is winding down operations just as two new companies, Borealis Biosciences and GondolaBio, are launching. Meanwhile, in the midst of already tense relations with China, House lawmakers raise the alarm about U.S. companies working with the country’s military on trials. August 28, 2024. ·.
About Us - BioSpace
网页About Us. BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The proprietary resources we provide help companies make informed decisions regarding their workforce ...
Novartis Eyes Rare Kidney Disease Approvals on Heels of Two ... - BioSpace
网页2024年5月28日 · Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the weekend. Results from the Phase III ALIGN study showed that at 36 weeks, Novartis’ investigational endothelin A (ETA) receptor antagonist atrasentan reduced ...
Approvals - BioSpace
网页FDA. Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara. Pyzchiva, developed by Samsung Bioepis, will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson’s Janssen Biotech. July 1, 2024.
Clinical research - BioSpace
网页2024年8月12日 · Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1. August 13, 2024. 4 min read. Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis.
BIOSECURE Act Could Signal a Seismic Shift for Biopharma in US …
网页2024年7月31日 · Over the past decade, China has become one of the largest suppliers of pharmaceuticals for the U.S. In 2023 alone, companies including Merck, GSK and AstraZeneca invested over $44.1 billion in biotech licensing deals with Chinese drugmakers. Pharmaceutical imports from China rose 485% in two years, from $2.1 billion in 2020 to $10.3 billion in 2022.. A May 2024 survey by the Biotechnology ...
Asia - BioSpace
网页House Speaker Plans to Vote, Pass BIOSECURE Act into Law This Year. House Speaker Mike Johnson (R-La.) on Monday said he intends to have a “significant package of China-related legislation” signed into law by the end of this year, including the BIOSECURE Act which intends to stop federal contracts with Chinese “companies of concern ...
Biotech, Medical Device & Pharma Startup News | BioSpace
网页2024年6月26日 · Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market. 4/18/2024. The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly.